The Journal of
Clinical Psychiatry

Addiction

Book Review July 21, 2009

Recognition and Prevention of Major Mental and Substance Use Disorders

J Clin Psychiatry 2009;70(7):1060-1060

Article Abstract

From our regular book review column.

Each year, the American Psychopathological Association
(APPA) holds one of the best meetings available for psychiatric
investigators. In 2005, the meeting focused on the prevention of
psychiatric disorders and substance use disorders. This volume
derives from the presentations at that meeting.

Download Free PDF

Save Save

Cite

Advertisement
GAM ID: sidebar-top

INFORMATION FROM INDUSTRY

AUVELITY is an FDA-approved treatment for adults with MDD. Auvelity, is a rapid-acting antidepressant with a multimodal mechanism, targeting both glutamatergic and monoaminergic pathways. Learn more about how AUVELITY is thought to work and side effects. Please see Important Safety Information within this document and the full Prescribing Information.

Advertisement
GAM ID: sidebar-bottom

Vol 85 • 2024 • Number 3

Read the Current Issue

Editorial

Focus on Women’s Mental Health: Twenty Years and Counting

Original Research

Esmethadone in Patients With Major Depressive Disorder and Inadequate Response to Standard Antidepressants

Commentary

Can Our Collective Experiences As Clinicians Improve Mental Health Care?

Original Research

Prescription Opioid Use Disorder in US Adults Reporting Prescription Opioid Use

Original Research

Symptomatic Disorders Comorbid with Borderline Personality Disorder Over Time

Original Research

Aripiprazole Lauroxil Initiation Regimens

View current Issue